Hayat Pharmaceutical Industries Co (AMM:HPIC) EBIT: JOD2.61 Mil (TTM As of Mar. 2026)


AMM:HPIC Hayat Pharmaceutical Industries Co AMM:HPIC
79 GF Score
Price JOD3.12
GF Value JOD2.74
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Hayat Pharmaceutical Industries Co EBIT?

Hayat Pharmaceutical Industries Co AMM:HPIC 79 EBIT is JOD2.61 Mil as of Mar. 2026. GuruFocus rates AMM:HPIC with a GF Score™ of 79/100 and a GF Value™ of JOD2.74 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Hayat Pharmaceutical Industries Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was JOD0.21 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was JOD2.61 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Hayat Pharmaceutical Industries Co's annualized ROC % for the quarter that ended in Mar. 2026 was 1.79%. Hayat Pharmaceutical Industries Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 4.07%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Hayat Pharmaceutical Industries Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 11.03%.

Hayat Pharmaceutical Industries Co  (AMM:HPIC) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Hayat Pharmaceutical Industries Co's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=0.564 * ( 1 - 15.47% )/( (26.326 + 26.805)/ 2 )
=0.4767492/26.5655
=1.79 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=37.422 - 1.535 - ( 9.561 - max(0, 3.881 - 24.521+9.561))
=26.326

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=38.675 - 1.561 - ( 10.309 - max(0, 4.346 - 25.064+10.309))
=26.805

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Hayat Pharmaceutical Industries Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=0.844/( ( (12.677 + max(4.636, 0)) + (13.37 + max(10.79, 0)) )/ 2 )
=0.844/( ( 17.313 + 24.16 )/ 2 )
=0.844/20.7365
=4.07 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4.506 + 2.612 + 0.398) - (1.535 + 0 + 1.345)
=4.636

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(10.623 + 3.304 + 0) - (1.561 + 0 + 1.576)
=10.79

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Hayat Pharmaceutical Industries Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=2.608/23.653
=11.03 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hayat Pharmaceutical Industries Co EBIT Related Terms

Hayat Pharmaceutical Industries Co EBIT Historical Data

* Premium members only.

The historical data trend for Hayat Pharmaceutical Industries Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hayat Pharmaceutical Industries Co EBIT Chart

Hayat Pharmaceutical Industries Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.42 4.20 2.84 3.69 2.94

Hayat Pharmaceutical Industries Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.55 0.49 0.87 1.04 0.21

AMM:HPIC vs ZTS, UTHR, VTRS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Hayat Pharmaceutical Industries Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hayat Pharmaceutical Industries Co EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hayat Pharmaceutical Industries Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Hayat Pharmaceutical Industries Co's EV-to-EBIT falls into.


AMM:HPIC
79GF Score
Hayat Pharmaceutical Industries Co AMM:HPIC
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hayat Pharmaceutical Industries Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was JOD2.61 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of JOD2.61 Mil mean?
Hayat Pharmaceutical Industries Co (AMM:HPIC) has a EBIT of JOD2.61 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Hayat Pharmaceutical Industries Co.
Is Hayat Pharmaceutical Industries Co's EBIT too high?
Hayat Pharmaceutical Industries Co's current EBIT is JOD2.61 Mil. Overall, Hayat Pharmaceutical Industries Co has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hayat Pharmaceutical Industries Co's EBIT compare to ZTS and UTHR?
Hayat Pharmaceutical Industries Co's EBIT of JOD2.61 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Hayat Pharmaceutical Industries Co. Hayat Pharmaceutical Industries Co's current EBIT is JOD2.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hayat Pharmaceutical Industries Co stock overvalued right now?
Based on GuruFocus' analysis, Hayat Pharmaceutical Industries Co (AMM:HPIC) is currently considered Modestly Overvalued. The stock's GF Value™ is JOD2.74, compared to a current price of JOD3.12 — trading 13.9% above its estimated fair value. The current EBIT is JOD2.61 Mil. Hayat Pharmaceutical Industries Co's overall GF Score™ is 79/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Hayat Pharmaceutical Industries Co (AMM:HPIC), the current EBIT is JOD2.61 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hayat Pharmaceutical Industries Co (AMM:HPIC) Overvalued in 2026?

Based on GuruFocus' analysis, Hayat Pharmaceutical Industries Co stock appears to be overvalued. The current stock price of JOD3.12 is trading 13.9% above its estimated GF Value™ of JOD2.74. GuruFocus considers Hayat Pharmaceutical Industries Co to be Modestly Overvalued.

Key valuation signals for AMM:HPIC:

  • EBIT: JOD2.61 Mil
  • GF Value™: JOD2.74 vs. price of JOD3.12 (13.9% above fair value)
  • GF Score™: 79/100 with 6 warning signs

No single metric tells the full story. See the AMM:HPIC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hayat Pharmaceutical Industries Co Business Description

Address Mohammed Ali Alkurdi St. Al-Rajeeb Amman, 1564 Amman, Amman, JOR, 11118
Hayat Pharmaceutical Industries Co is a Jordan based pharmaceutical manufacturing company. The princapal activity is producing human and veterinary medicines in all its forms and medical stickers and stockings, in addition to the production of medical supplies, body care lotions, cosmetics, sutures and initiating marketing campgains as well as import and export operations. Its products include Cardiovascular system, Infectious disease, Dermatology, Gastrointestinal system, Inner Ear & Balance, Men's Health, Neurology, Vitamins & Supplements, Women's Health, and Respiratory system. The operations business operating within one geographic sector which is the Hashemite Kingdom of Jordan.
79GF Score

Get the complete analysis for AMM:HPIC

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

JOD3.12
Price
JOD2.74
GF Value